We propose that patients with more severe nigrostriatal lesion, that is, more advanced disease, might be more susceptible to experiencing a deterioration of Parkinsonism upon treatment with a SERT-selective MAUI. This evidence concerns the gene SLC6A4 and Parkinsonism.